Global Antinuclear Antibody Test Market to Witness Widespread Growth with Growing Prevalence of Autoimmune Diseases Worldwide

Generally, antinuclear antibodies attack the tissues in a human body— specifically targeting the nucleus of each cell. An antinuclear antibody test is used to examine whether a person has an autoimmune disorder, a condition in which the immune system attacks healthy cells in the body. Nowadays, the prevalence of autoimmune diseases is increasing rapidly. However, studies based on systematic data are inadequate, so it is still unclear whether the rise in cases of autoimmune diseases is merely owing to developments in diagnosis and reporting.

There are a number of factors that can trigger an autoimmune disease, such as poor diet, stress, lack of workout, inadequate sleep, and smoking. As all these factors are highly prevalent in today’s generation, the rate of occurrence of autoimmune diseases has also surged. This has greatly accelerated the growth of the antinuclear antibody test market in recent years.

Newest Insights in the Antinuclear Antibody Test Market

As per a report by Research Dive, the global antinuclear antibody test market is expected to grow with a 14.97% CAGR and surpass $4,999.40 million in the 2022–2031 timeframe. The North America antinuclear antibody test market is expected to perceive significant growth with a CAGR of 13.85% in the years to come. This is because of the growing incidence of autoimmune diseases in the region. Moreover, there is high demand for early diagnosis and effective treatment of autoimmune diseases in this region owing to numerous factors such as the growing elderly population which is more vulnerable to diseases due to weak immunity.  In addition, rising investments in the U.S. for developing advanced antinuclear antibody tests is predicted to drive the growth of the regional market.

How are the Market Players Responding to the Rising Demand for Antinuclear Antibody Tests?

A significant increase in the cases of chronic ailments across the globe is propelling the demand for antinuclear antibody tests. Market players are greatly investing in innovative research and developments to cater to the rising demand for antinuclear antibody tests. Some of the foremost players in the antinuclear antibody test market are Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Immuno Concepts NA Ltd., Thermo Fisher Scientific, EUROIMMUN Medizinische Labordiagnostika AG, Inova Diagnostics, Inc., Erba Diagnostics, Alere Inc., ZEUS Scientific, Inc, Antibodies Incorporated, and others. These players are focused on planning and devising tactics such as mergers and acquisitions, collaborations, novel advances, and partnerships to reach a notable position in the global market.

For instance,

• In August 2018, Inova Diagnostics, a global frontrunner in autoimmune disease diagnostic systems and reagents for the clinical laboratory, announced the clearance of QUANTA Flash® HMGCR by the U.S. Food and Drug Administration (FDA).
• In October 2020, Thermo Fisher Scientific, a key player in the antinuclear antibody test industry, developed two novel SARS-CoV-2 antibody tests termed: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test.
• In June 2022, Thermo Fisher Scientific, Inc., an American supplier of scientific instrumentation, reagents and consumables, and software services, obtained FDA approval for Autoimmune Disease Test - EliA RNA Polymerase III and EliA Rib-P blood tests - developed to detect Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE).

COVID-19 Impact on the Global Antinuclear Antibody Test Market

The outbreak of the coronavirus pandemic in 2020 has optimistically impacted the global antinuclear antibody test market. During the pandemic period, an unpredicted surge has been observed in the demand for antinuclear antibody tests in healthcare centers as COVID-19 patients have greater chances of acquiring autoimmune diseases. The antinuclear antibody test market observed massive growth during the disastrous situations of the pandemic due to the rising need for early diagnosis tests, which boosted the use of antinuclear antibody tests. As per market experts, the global market is projected to observe massive growth, even after the relaxation of the pandemic, in the forthcoming years.